サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468258

がん性悪液質市場レポート：治療薬、作用機序、流通チャネル、地域別、2024年～2032年

Cancer Cachexia Market Report by Therapeutics, Mode of Action, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
がん性悪液質市場レポート：治療薬、作用機序、流通チャネル、地域別、2024年～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん性悪液質の市場規模は2023年に21億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに30億米ドルに達し、2024年から2032年の間に4.1%の成長率（CAGR）を示すと予測しています。

がん悪液質は、多因子性、宿主-貪食性、消耗性症候群を指し、組織的炎症、除脂肪体重の不随意的減少、負の蛋白バランス、食欲不振、筋萎縮を特徴とします。結核、多発性硬化症、慢性閉塞性肺疾患（COPD）、ヒト免疫不全ウイルス（HIV）など、さまざまな慢性疾患の発症によって引き起こされます。がん性悪液質は、黄体ホルモン、コルチコステロイド、併用療法などの様々な治療薬を利用して治療することができます。これらのうち、黄体ホルモンは食欲を改善し体重増加を促進する合成または天然のステロイドホルモンであり、コルチコステロイドは炎症を緩和し、過剰な免疫系を抑制するのに役立ちます。

がん性悪液質の市場動向：

がんと悪液質の有病率の増加、特に増加する老年人口の間で、先進的な治療法と薬剤の需要が促進されており、これが市場の成長を主に促進しています。これはさらに、がん性悪液質を治療する新規治療薬の利用可能性に関する消費者の意識の高まりにも支えられています。さらに、薬物療法、非薬物療法、臨床試験を通じて除脂肪体重（LBM）を改善するための併用療法への患者の傾斜が、もう一つの成長促進要因として作用しています。これに伴い、消化を改善するために酢酸メゲストロール、デキサメタゾン、メチルプレドニゾロンなどの食欲増進剤が広く利用されていることも、市場の成長に寄与しています。さらに、がん性悪液質治療のための効果的な医薬品の市場開拓に重点を置いた著しい技術進歩が、市場の成長をさらに促進しています。これとは別に、がん性悪液質の原因や症状、高度な治療法を使用することの利点について人々を啓発するために、さまざまな国の政府機関や非政府組織（NGO）によって実施されている数多くの有利な取り組みが、市場に前向きな見通しを生み出しています。

本レポートで扱う主な質問

  • 2023年の世界がん悪液質市場規模は？
  • 2024-2032年の世界のがん性悪液質市場の予想成長率は？
  • 世界のがん性悪液質市場を牽引する主要因は何か？
  • COVID-19が世界のがん悪液質市場に与えた影響は？
  • 治療薬に基づく世界のがん性悪液質市場の内訳は？
  • 作用機序に基づく世界のがん性悪液質市場の内訳は？
  • 世界のがん性悪液質市場における主要地域は？
  • 世界のがん性悪液質市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のがん悪液質市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療薬別

  • 黄体ホルモン
    • 市場動向
    • 市場予測
  • 副腎皮質ホルモン
    • 市場動向
    • 市場予測
  • 併用療法
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：作用機序別

  • 食欲増進剤
    • 市場動向
    • 市場予測
  • 体重減少安定剤
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院店舗
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AAVogen Inc.
    • Actimed Therapeutics Ltd.
    • Aphios Corporation
    • Artelo Biosciences Inc.
    • AVEO Pharmaceuticals Inc.
    • Fresenius Kabi AG（Fresenius SE & Co. KGaA）
    • Helsinn Healthcare SA
    • Merck & Co. Inc.
    • NGM Biopharmaceuticals Inc.
    • Pfizer Inc.
    • Tetra Bio-Pharma
図表

List of Figures

  • Figure 1: Global: Cancer Cachexia Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Cachexia Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Cachexia Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer Cachexia Market: Breakup by Therapeutics (in %), 2023
  • Figure 5: Global: Cancer Cachexia Market: Breakup by Mode of Action (in %), 2023
  • Figure 6: Global: Cancer Cachexia Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Cancer Cachexia Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cancer Cachexia (Progestogens) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Cancer Cachexia (Progestogens) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Cancer Cachexia (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cancer Cachexia (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cancer Cachexia (Combination Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cancer Cachexia (Combination Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cancer Cachexia (Other Therapeutics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cancer Cachexia (Other Therapeutics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cancer Cachexia (Appetite Stimulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cancer Cachexia (Appetite Stimulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cancer Cachexia (Weight Loss Stabilizers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cancer Cachexia (Weight Loss Stabilizers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cancer Cachexia (Hospital Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cancer Cachexia (Hospital Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cancer Cachexia (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cancer Cachexia (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cancer Cachexia (Online Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cancer Cachexia (Online Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Cancer Cachexia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Cancer Cachexia Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Cancer Cachexia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Cancer Cachexia Industry: SWOT Analysis
  • Figure 76: Global: Cancer Cachexia Industry: Value Chain Analysis
  • Figure 77: Global: Cancer Cachexia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Cachexia Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Cachexia Market Forecast: Breakup by Therapeutics (in Million US$), 2024-2032
  • Table 3: Global: Cancer Cachexia Market Forecast: Breakup by Mode of Action (in Million US$), 2024-2032
  • Table 4: Global: Cancer Cachexia Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Cancer Cachexia Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cancer Cachexia Market: Competitive Structure
  • Table 7: Global: Cancer Cachexia Market: Key Players
目次
Product Code: SR112024A5338

The global cancer cachexia market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.

Cancer Cachexia Market Trends:

The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer cachexia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutics, mode of action and distribution channel.

Breakup by Therapeutics:

Progestogens

Corticosteroids

Combination Therapy

Others

Breakup by Mode of Action:

Appetite Stimulators

Weight Loss Stabilizers

Breakup by Distribution Channel:

Hospital Stores

Retail Pharmacy

Online Pharmacy

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.

Key Questions Answered in This Report

  • 1. What was the size of the global cancer cachexia market in 2023?
  • 2. What is the expected growth rate of the global cancer cachexia market during 2024-2032?
  • 3. What are the key factors driving the global cancer cachexia market?
  • 4. What has been the impact of COVID-19 on the global cancer cachexia market?
  • 5. What is the breakup of the global cancer cachexia market based on the therapeutics?
  • 6. What is the breakup of the global cancer cachexia market based on the mode of action?
  • 7. What are the key regions in the global cancer cachexia market?
  • 8. Who are the key players/companies in the global cancer cachexia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Cachexia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutics

  • 6.1 Progestogens
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Corticosteroids
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Combination Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Mode of Action

  • 7.1 Appetite Stimulators
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Weight Loss Stabilizers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Stores
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AAVogen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Actimed Therapeutics Ltd.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Aphios Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Artelo Biosciences Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 AVEO Pharmaceuticals Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Fresenius Kabi AG (Fresenius SE & Co. KGaA)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 Helsinn Healthcare SA
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Merck & Co. Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 NGM Biopharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Tetra Bio-Pharma
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials